Vanda Pharmaceuticals Inc (NAS:VNDA)
$ 5.04 -0.11 (-2.14%) Market Cap: 293.87 Mil Enterprise Value: -68.03 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 81/100

Q2 2020 Vanda Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2020 / 08:30PM GMT
Release Date Price: $11.02 (+1.75%)
Operator

Welcome to the Q2 2020 Vanda Pharmaceuticals, Inc. Earnings Conference Call. My name is Vanessa, and I'll be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the call over to Kevin Moran, Vanda's Senior Vice President and Chief Financial Officer. Kevin, you may begin.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - CFO, VP & Treasurer

Thank you, Vanessa. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' second quarter 2020 performance. Our second quarter 2020 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihales Polymeropoulos, our President and CEO. Following my introductory remarks, Mihales will update you on our ongoing activities, I will then comment on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot